Feng Shen

18.5k citations

285 papers · 9.9k · 3 hit papers · h-index 54

Impact in

Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism

Papers in

Surgery 99
- Cholangiocarcinoma and Gallbladder Cancer Studies 94
Hepatology 96
- Hepatocellular Carcinoma Treatment and Prognosis 92

Co-authors: Mengchao Wu (55 shared papers)Yong Xia (37 shared papers)Kui Wang (31 shared papers)Wan Yee Lau (67 shared papers)Dong Wu (18 shared papers)Tian Yang (66 shared papers)Timothy M. Pawlik (76 shared papers)Xuying Wan (19 shared papers)
Journals: Annals of Surgical Oncology (34 papers)HPB (27 papers)Journal of Surgical Oncology (16 papers)Journal of Gastrointestinal Surgery (13 papers)Surgery (11 papers)
Partner nations: China United States Hong Kong

In The Last Decade

Feng Shen

268 papers receiving 9.8k citations

Feng Shen's Hit Papers

align trajectories log scale

Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma 2018 · 377 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 JAMA Surgery
2015 JAMA Surgery
2013 Journal of Clinical Oncology

Peers

Countries citing papers authored by Feng Shen

Since Specialization

Citations

This map shows the geographic impact of Feng Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Shen more than expected).

Fields of papers citing papers by Feng Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Shen. The network helps show where Feng Shen may publish in the future.

Co-authors

The 25 scholars most cited alongside Feng Shen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Feng Shen Line = papers co-authored together Feng Shen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 285 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy Journal of Clinical Oncology ·Yizhou Wang, Jun Li, Yong Xia, Renyan Gong, Kui Wang, Zhenlin Yan, Xuying Wan, Guanghua Liu, Dong Wu, Lehua Shi, W. Y. Lau, Mengchao Wu, Feng Shen Hit paper breakdown →	2013	849
2	Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus–Related Hepatocellular Carcinoma Within the Milan Criteria JAMA Surgery ·Zhengqing Lei, Jun Li, Dong Wu, Yong Xia, Qing Wang, Anfeng Si, Kui Wang, Xuying Wan, Wan Yee Lau, Mengchao Wu, Feng Shen Hit paper breakdown →	2015	466
3	Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma JAMA Surgery ·Xin‐Fei Xu, Hao Xing, Jun Han, Zhenli Li, W. Y. Lau, Ya-Hao Zhou, Wei‐Min Gu, Hong Wang, Ting‐Hao Chen, Yongyi Zeng, Chao Li, Mengchao Wu, Feng Shen, Tian Yang Hit paper breakdown →	2018	377
4	Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice Hepatology ·Liang Li, Lei Chen, Liang Hu, Yuan Liu, Hanyong Sun, Jing Tang, Yu-Jie Hou, Yan–Xin Chang, Qianqian Tu, Gen‐Sheng Feng, Feng Shen, Mengchao Wu, Hongyang Wang	2011	207
5	The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma Journal of Hepatology ·Lei Chen, He‐Xin Yan, Wen Yang, Liang Hu, Le-Xin Yu, Qiong Liu, Li Liang, Dandan Huang, Jin Ding, Feng Shen, Weiping Zhou, Mengchao Wu, Hongyang Wang	2008	198
6	Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection Annals of Surgical Oncology ·Gaya Spolverato, Yuhree Kim, Sorin Alexandrescu, Hugo P. Marques, Jorge Lamelas, Luca Aldrighetti, T. Clark Gamblin, Shishir K. Maithel, Carlo Pulitanò, Todd W. Bauer, Feng Shen, George A. Poultsides, Thuy B. Tran, J. Wallis Marsh, Timothy M. Pawlik	2015	190
7	Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription Journal of Hepatology ·Qinjunjie Chen, Haibo Wang, Zheng Li, Fengwei Li, Leilei Liang, Yiran Zou, Hao Shen, Jun Li, Yong Xia, Zhangjun Cheng, Tian Yang, Kui Wang, Feng Shen	2021	179
8	Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent British journal of surgery ·X. F. Zhang, Eliza W. Beal, Fabio Bagante, Jeffery Chakedis, Matthew J. Weiss, Irinel Popescu, Hugo P. Marques, Luca Aldrighetti, Shishir K. Maithel, Carlo Pulitanò, Thomas W. Bauer, Feng Shen, George A. Poultsides, Olivier Soubrane, Guillaume Martel, Bas Groot Koerkamp, E. Itaru, Timothy M. Pawlik	2017	173
9	High Serum Levels of Cholesterol Increase Antitumor Functions of Nature Killer Cells and Reduce Growth of Liver Tumors in Mice Gastroenterology ·Wenhao Qin, Zhishi Yang, Mian Li, Yao Chen, Xiaofang Zhao, Yingyi Qin, Jiaqi Song, Bi-Bo Wang, Bo Yuan, Xiuliang Cui, Feng Shen, Jia He, Yufang Bi, Guang Ning, Jing Fu, Hongyang Wang	2020	155
10	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma JAMA Surgery ·Katiuscha Merath, Qinyu Chen, Fabio Bagante, Sorin Alexandrescu, Hugo P. Marques, Luca Aldrighetti, Shishir K. Maithel, Carlo Pulitanò, Matthew J. Weiss, Todd W. Bauer, Feng Shen, George A. Poultsides, Olivier Soubrane, Guillaume Martel, Bas Groot Koerkamp, Alfredo Guglielmi, Endo Itaru, Jordan M. Cloyd, Timothy M. Pawlik	2019	154
11	Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection HPB ·Zhangjun Cheng, Pinghua Yang, Shuping Qu, Jiahua Zhou, Jue Yang, Xinwei Yang, Yong Xia, Jun Li, Kui Wang, Zhenlin Yan, Dong Wu, Baohua Zhang, Norbert Hüser, Feng Shen	2014	135
12	Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival World Journal of Surgery ·Lu Wu, Diamantis I. Tsilimigras, Anghela Z. Paredes, Rittal Mehta, J. Madison Hyer, Katiuscha Merath, Kota Sahara, Fabio Bagante, Eliza W. Beal, Feng Shen, Timothy M. Pawlik	2019	126
13	Can hepatic resection provide a long‐term cure for patients with intrahepatic cholangiocarcinoma? Cancer ·Gaya Spolverato, Alessandro Vitale, Alessandro Cucchetti, Irinel Popescu, Hugo P. Marques, Luca Aldrighetti, T. Clark Gamblin, Shishir K. Maithel, Charbel Sandroussi, Todd W. Bauer, Feng Shen, George A. Poultsides, J. Wallis Marsh, Timothy M. Pawlik	2015	122
14	The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma Annals of Surgical Oncology ·Gaya Spolverato, Mohammad Yawar Yakoob, Yuhree Kim, Sorin Alexandrescu, Hugo P. Marques, Jorge Lamelas, Luca Aldrighetti, T. Clark Gamblin, Shishir K. Maithel, Carlo Pulitanò, Todd W. Bauer, Feng Shen, George A. Poultsides, J. Wallis Marsh, Timothy M. Pawlik	2015	121
15	p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways Hepatology ·Jing Fu, Yao Chen, Jie Cao, Tao Luo, You‐Wen Qian, Wen Yang, Yibin Ren, Bo Su, Guangwen Cao, Yuan Yang, Yiqun Yan, Feng Shen, Mengchao Wu, Gen‐Sheng Feng, Hongyang Wang	2010	110
16	Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma Surgery ·Alessandro Cucchetti, Guoliang Qiao, Matteo Cescon, Jun Li, Yong Xia, Giorgio Ercolani, Feng Shen, Antonio Daniele Pinna	2013	107
17	Critical role of TRPC6 channels in VEGF-mediated angiogenesis Cancer Letters ·Ruiliang Ge, Yilin Tai, Yuanyuan Sun, Kechun Zhou, Shenglian Yang, Tian‐Lin Cheng, Qifei Zou, Feng Shen, Yizheng Wang	2009	106
18	Overexpression of Aspartyl-(Asparaginyl)-β-Hydroxylase in Hepatocellular Carcinoma Is Associated With Worse Surgical Outcome Hepatology ·Kui Wang, Jian Liu, Zhenlin Yan, Jun Li, Lehua Shi, Wen‐Ming Cong, Yong Xia, Qifei Zou, Tao Xi, Feng Shen, Hongyang Wang, Mengchao Wu	2010	94
19	Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma Annals of Surgical Oncology ·Liang-Shuo Hu, Xu‐Feng Zhang, Matthew J. Weiss, Irinel Popescu, Hugo P. Marques, Luca Aldrighetti, Shishir K. Maithel, Carlo Pulitanò, Todd W. Bauer, Feng Shen, George A. Poultsides, Olivier Soubrane, Guillaume Martel, Bas Groot Koerkamp, Endo Itaru, Timothy M. Pawlik	2019	86
20	RNA-Seq Analyses Generate Comprehensive Transcriptomic Landscape and Reveal Complex Transcript Patterns in Hepatocellular Carcinoma PLoS ONE ·Qichao Huang, Biaoyang Lin, Han-Qiang Liu, Xi Ma, Fan Mo, Wei Yu, Lisha Li, Hongwei Li, Tian Tian, Dong Wu, Feng Shen, Jinliang Xing, Zhi‐Nan Chen	2011	86

About Feng Shen

Feng Shen is a scholar working on Surgery, Hepatology, Oncology, Molecular Biology and Cancer Research, having authored 285 papers that have together received 9.9k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (94 papers), Hepatocellular Carcinoma Treatment and Prognosis (92 papers), Liver Disease Diagnosis and Treatment (14 papers), Cancer, Lipids, and Metabolism (11 papers), Gallbladder and Bile Duct Disorders (10 papers), Hepatitis B Virus Studies (9 papers), Nanoplatforms for cancer theranostics (7 papers) and Inflammatory Biomarkers in Disease Prognosis (6 papers). The work is most often cited by research in Hepatology (2.9k citations), Cancer Research (1.3k citations), Surgery (3.4k citations), Oncology (1.6k citations) and Pulmonary and Respiratory Medicine (1.3k citations). Feng Shen has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Mengchao Wu, Yong Xia, Kui Wang, Wan Yee Lau, Dong Wu, Tian Yang, Timothy M. Pawlik, Xuying Wan, Jun Li and Hugo P. Marques. Their work appears in journals such as Annals of Surgical Oncology, HPB, Journal of Surgical Oncology, Journal of Gastrointestinal Surgery and Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Feng Shen

Impact in

Papers in i

In The Last Decade

Feng Shen

Feng Shen's Hit Papers

Peers

Countries citing papers authored by Feng Shen

Fields of papers citing papers by Feng Shen

All Works

About Feng Shen

Explore authors with similar magnitude of impact

Papers in